List of Excipients in Branded Drug SUFLAVE

« Back to Dashboard

SUFLAVE Excipient Strategy and Commercial Opportunities

Last updated: October 19, 2026

SUFLAVE is a prescription bowel-preparation product approved by the FDA in 2023 for cleansing the colon before colonoscopy in adults. Its formulation combines polyethylene glycol 3350 with sulfate, chloride, potassium, sodium ascorbate, and ascorbic acid salts. The commercial opportunity is concentrated in tolerability, flavor, dose completion, manufacturing reliability, and differentiation from generic polyethylene glycol-electrolyte solutions rather than in a novel active pharmaceutical ingredient.[1]

What is SUFLAVE and how does its formulation work?

SUFLAVE is a split-dose oral solution product supplied as a powder that is reconstituted with water. The formulation uses a high molecular weight osmotic polymer and electrolytes to induce rapid bowel evacuation while limiting net absorption of water and ions.

Component	Functional role
Polyethylene glycol 3350	Osmotic agent that retains water in the gastrointestinal tract
Sodium sulfate	Electrolyte and osmotic component
Sodium chloride	Replaces sodium and chloride losses
Potassium chloride	Replaces potassium losses
Sodium ascorbate	Osmotic electrolyte and ascorbate source
Ascorbic acid	Osmotic component and acidity modifier
Flavoring system	Improves palatability
Sucralose or other sweetener system	Masks acidity and mineral taste, subject to current labeling

The preparation is administered in two doses. Each dose is mixed with water, followed by additional clear liquid. The regimen is designed to reduce the volume of the active preparation compared with some older polyethylene glycol products, while preserving a total hydration requirement that remains clinically material.[1]

How does SUFLAVE compare with conventional bowel preparations?

SUFLAVE competes with four major formulation groups:

1. High-volume polyethylene glycol-electrolyte solutions.
2. Low-volume polyethylene glycol-electrolyte products.
3. Sulfate-based preparations.
4. Sodium picosulfate, magnesium oxide, and citric acid products.

Its differentiation is based on a combination of polyethylene glycol use, split dosing, flavoring, low active-solution volume, and patient-oriented administration instructions. The product does not eliminate the need for substantial clear-liquid intake.

Product characteristic	SUFLAVE	Conventional high-volume PEG solution	Sodium picosulfate-based product
Primary osmotic agent	PEG 3350 plus salts and ascorbate	PEG plus electrolytes	Picosulfate, magnesium, citric acid
Active preparation volume	Lower than traditional 4-liter products	Often approximately 4 liters	Low
Follow-on clear liquid	Required	Required	Required
Flavor and adherence importance	High	High	High
Electrolyte and renal-risk considerations	Material	Material	Material
Generic substitution pressure	Expected over time	High	Moderate to high

What excipients create the main commercial value in SUFLAVE?

The largest commercial value is likely in the sensory and administration package rather than in conventional excipients that are difficult to reproduce.

Flavoring and sweetness

Bowel preparations are vulnerable to poor adherence because of salty, acidic, bitter, or medicinal taste. A lemon-lime or similar flavor system can improve acceptability, but the relevant performance measure is whether patients complete both doses and the required follow-on fluids.

A commercially effective flavor system must manage several taste defects at once:

• Sulfate-associated bitterness and salinity.
• Ascorbic acid acidity.
• Potassium chloride bitterness.
• Mineral aftertaste.
• High solution volume.
• Repeated exposure over a short dosing period.

Sucralose or another high-intensity sweetener can reduce sugar content and limit osmotic contribution from the sweetener itself. The formulation must avoid excessive sweetness, which can worsen nausea during consumption.

The best development strategy is not a single flavor screen. It is a matrix evaluating flavor intensity, acid balance, aftertaste, mouthfeel, cold-temperature performance, and dose-completion behavior.

Polyethylene glycol grade

PEG 3350 is a well-established pharmaceutical ingredient. Its molecular-weight distribution, impurity profile, moisture content, and powder flow can affect reconstitution and product consistency.

A supplier-change strategy should control:

• Average molecular weight and distribution.
• Residual ethylene oxide and 1,4-dioxane.
• Water content.
• Bulk density.
• Particle-size distribution.
• Microbial quality.
• Dissolution time.
• Compatibility with the electrolyte and flavor system.

PEG is not a strong standalone barrier to competition because multiple qualified suppliers and established compendial controls exist. The commercial value lies in the finished blend and its manufacturing process.

Acid-base and electrolyte balance

The formulation must maintain a defined pH and osmolality after reconstitution. Small changes in acid, ascorbate, sulfate, or chloride content can affect taste, stability, dissolution, and gastrointestinal tolerability.

Potential formulation-development opportunities include:

• Reducing perceived saltiness without changing electrolyte exposure.
• Improving dissolution at refrigerated and room temperatures.
• Limiting precipitation or haze.
• Reducing foaming during mixing.
• Controlling pH drift during shelf life.
• Improving powder uniformity across the bottle.

These improvements may support line extensions or manufacturing know-how, although many will be difficult to protect broadly through composition patents.

What manufacturing and packaging barriers affect SUFLAVE?

The powder is moisture-sensitive because the formulation contains hygroscopic salts, acids, ascorbate, and PEG. Moisture uptake can cause caking, segregation, assay drift, poor flow, and slower reconstitution.

Manufacturing controls

A robust process should address:

Manufacturing issue	Commercial consequence
Hygroscopicity	Caking and reduced powder flow
Segregation	Dose nonuniformity
Electrostatic charging	Losses during blending and filling
Flavor volatility	Reduced sensory performance
Blend uniformity	Assay and dose consistency risk
Moisture ingress	Stability failures
Poor dissolution	Lower patient acceptability
Cleaning difficulty	Cross-contamination and downtime

The order of ingredient addition, blend time, relative particle size, and humidity control can materially affect finished-product quality. A premix strategy may be needed for low-dose flavoring or sweetener components to prevent content-uniformity problems.

Packaging opportunities

Packaging is part of the excipient strategy because it protects the formulation before reconstitution. The most relevant options include:

• High-barrier plastic bottles.
• Induction-sealed closures.
• Desiccant integration where compatible with the dosing design.
• Unit-dose or dual-dose packaging.
• Child-resistant packaging.
• Tamper-evident packaging.
• Secondary cartons with clear mixing and timing instructions.

A dual-bottle kit supports split dosing but increases packaging material, assembly complexity, and shipping volume. A single-container design could reduce materials but may create dose-sequencing and patient-use risks.

Packaging improvements can also support commercial differentiation. A calendar-style dose guide, color-coded bottles, and prominent hydration instructions may reduce administration errors without changing the formulation.

What FDA regulatory status and exclusivity apply to SUFLAVE?

SUFLAVE was approved by FDA in June 2023 under NDA 217372 for adult colonoscopy preparation.[1] The product is prescription-only and is listed in FDA drug-labeling resources.

Regulatory item	Status
Product	SUFLAVE
Active formulation	PEG 3350 with sulfate, chloride, potassium, sodium ascorbate, and ascorbic acid components
Dosage form	Powder for oral solution
Route	Oral
Approval	June 2023
NDA	217372
Indication	Colon cleansing before colonoscopy in adults
FDA pathway	NDA
Orange Book relevance	NDA and any listed patents or exclusivities must be checked against the current FDA Orange Book

The three-year exclusivity framework for an NDA relying on new clinical investigations may restrict approval of certain abbreviated applications until the applicable exclusivity period expires. The precise exclusivity status should be determined from the current FDA Orange Book and FDA exclusivity listings rather than inferred solely from the approval date.[2]

What patents protect SUFLAVE?

The principal protectable assets may include:

• Finished-product composition claims.
• Specific electrolyte and ascorbate ratios.
• Flavoring or sweetness systems.
• Powder-blend manufacturing processes.
• Moisture-control packaging.
• Reconstitution and administration methods.
• Method-of-use claims for split-dose colonoscopy preparation.

Public FDA labeling establishes regulatory status, not the complete scope of patent protection. Patent expiration dates, listed patents, and Paragraph IV risks require a current review of the Orange Book, USPTO records, and federal litigation databases. A generic applicant could challenge listed patents through an ANDA Paragraph IV certification if applicable patents appear in the Orange Book.[2,3]

When could generic SUFLAVE competition emerge?

Generic entry depends on the regulatory pathway, listed patents, exclusivity, bioequivalence requirements, and the complexity of demonstrating equivalent pharmaceutical performance.

A generic applicant would likely need to address:

1. Active ingredient and electrolyte equivalence.
2. Finished-product assay and uniformity.
3. Dissolution and reconstitution behavior.
4. Stability under the proposed packaging.
5. Labeling and administration instructions.
6. Flavor and inactive-ingredient differences.
7. Manufacturing controls for moisture-sensitive powder.

Taste may not always be a formal bioequivalence barrier, but it is a commercial barrier. A generic product with equivalent chemistry but weaker palatability could have difficulty winning prescriptions against the branded product.

What Paragraph IV and litigation risks exist?

The main Paragraph IV risk would arise if SUFLAVE has Orange Book-listed patents covering the finished composition, method of use, or formulation. Possible litigation issues include:

• Whether a generic product uses the claimed electrolyte ratio.
• Whether the generic performs the same split-dose method.
• Whether flavor or sweetener claims are drafted broadly enough to reach substitutes.
• Whether process claims can be infringed by a third-party manufacturer.
• Whether the branded company has granted a license or settlement to an ANDA filer.

No litigation, settlement date, or authorized-generic launch date should be assumed without a current docket and Orange Book review. Composition claims based on known PEG-electrolyte technology may face narrower enforceability than claims tied to a specific formulation, manufacturing process, or packaging configuration.

What commercial opportunities exist for SUFLAVE excipient innovation?

The strongest opportunities are incremental and patient-centered.

Improved sensory performance

A next-generation flavor system could target:

• Lower salt perception.
• Reduced acid bite.
• Less persistent aftertaste.
• Better performance when chilled.
• Faster taste recovery after each dose.
• Compatibility with common clear-liquid chasers.

A flavor system could be supplied as a platform technology to multiple bowel-preparation products, creating licensing potential beyond SUFLAVE.

Lower-volume and simplified regimens

A product that reduces active solution volume while preserving cleansing efficacy could compete directly with existing low-volume products. The constraint is that hydration cannot be reduced without considering renal, cardiovascular, and electrolyte risks.

Premium packaging

Packaging can support a premium position through:

• Dose-timed cartons.
• QR-linked preparation instructions.
• Pharmacy-ready adherence aids.
• Color-coded first- and second-dose bottles.
• Integrated measuring and mixing instructions.

These improvements are more likely to support lifecycle management, patient-support programs, and contracting differentiation than to create durable exclusivity by themselves.

Supplier and manufacturing licensing

Commercial opportunities may include licensing:

• Low-moisture powder-blending processes.
• Stable flavor systems for sulfate-containing preparations.
• High-barrier bottle and closure systems.
• PEG and electrolyte premixes.
• Process analytical technology for blend uniformity.
• Alternative sweeteners with improved aftertaste.

How strong is the SUFLAVE formulation and excipient patent estate?

The formulation’s technical defensibility is moderate, while its ingredient-level defensibility is likely limited. PEG 3350, sodium chloride, potassium chloride, sulfate salts, ascorbate, and ascorbic acid are established pharmaceutical materials. Broad claims covering those ingredients individually would face substantial prior-art exposure.

The stronger areas for protection are likely to be:

Asset	Relative protection potential
Individual excipients	Low
Broad PEG-electrolyte composition	Low to moderate
Narrow electrolyte ratios	Moderate
Flavor and sweetener combination	Moderate
Moisture-protective packaging	Moderate
Manufacturing process	Moderate
Administration regimen	Moderate, depending on claim scope
Patient-support materials	Low patent value, higher commercial value

What is the revenue exposure and competitive outlook?

SUFLAVE competes in a high-volume procedure market in which prescribing is influenced by gastroenterologist preference, patient completion, formulary status, pharmacy access, and net price. Revenue exposure is therefore tied to prescription share and payer coverage rather than to a high-cost chronic-treatment model.

The main commercial risks are:

• Generic PEG-electrolyte substitution.
• Formulary exclusion or higher copay.
• Competing low-volume bowel preparations.
• Safety concerns involving fluid and electrolyte shifts.
• Product shortages or packaging disruptions.
• Weak patient adherence despite improved flavor.
• Limited physician willingness to pay a premium.

The strongest defense is a combination of demonstrated completion rates, favorable tolerability, reliable supply, payer access, and a recognizable administration system. Excipient innovation supports that defense when it produces measurable improvements in dose completion or patient experience.

Key Takeaways

• SUFLAVE’s commercial differentiation depends on palatability, split dosing, active-solution volume, and administration convenience.
• The most important excipient variables are PEG quality, electrolyte balance, acid-base control, flavor, sweetness, and moisture protection.
• Ingredient-level patent protection is likely weaker than formulation, process, packaging, or method-of-use protection.
• Generic competition is likely to focus on chemical equivalence, reconstitution performance, manufacturing reliability, and price.
• Flavor technology, moisture-resistant packaging, and improved dose-completion systems offer the clearest lifecycle-management opportunities.
• Current Orange Book, USPTO, FDA exclusivity, and litigation records are required to establish exact patent numbers, expiration dates, Paragraph IV filings, or settlement terms.

FAQs

Is SUFLAVE a low-volume bowel preparation?

SUFLAVE uses a lower volume of active preparation than traditional 4-liter PEG solutions, but patients must consume additional clear liquids after each dose. Total fluid intake remains clinically important.

Which excipient most affects SUFLAVE patient acceptance?

The flavor and sweetener system has the greatest direct effect on patient acceptance. Sulfate, potassium chloride, and ascorbic acid create taste challenges that must be managed through flavor balance and administration instructions.

Can a generic SUFLAVE use a different flavor?

A generic product may use different inactive ingredients if it satisfies applicable FDA requirements. A different flavor could create commercial differentiation even if the active electrolyte composition is equivalent.

Are PEG 3350 and SUFLAVE interchangeable?

PEG 3350 alone is not equivalent to SUFLAVE. SUFLAVE contains PEG 3350 with a defined combination of sulfate, chloride, potassium, sodium ascorbate, and ascorbic acid components.

What is the best lifecycle strategy for SUFLAVE?

The strongest strategy combines sensory reformulation, lower moisture exposure, improved dose-timing tools, reliable supply, and evidence showing better completion or tolerability than competing bowel preparations.

References

1. U.S. Food and Drug Administration. (2023). SUFLAVE prescribing information. FDA and DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

3. U.S. Patent and Trademark Office. (2024). Patent Center. U.S. Department of Commerce.